Posttransplantation prophylaxis with primary high-dose hepatitis B immunoglobulin monotherapy and complementary preemptive antiviral add-on

Liver Transplantation

Volumn 17, Issue 4, 2011, Pages 456-465

  Hwang, Shin ^a   Ahn, Chul Soo ^a   Song, Gi Won ^a   Kim, Ki Hun ^a   Moon, Deok Bog ^a   Oh, Heung Bum ^a   Lim, Young Suk ^a   Lee, Han Chu ^a   Ha, Tae Yong ^a   Jung, Dong Hwan ^a   Chung, Young Hwa ^a   Lee, Sung Gyu ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ARGININE; ENTECAVIR; GLYCINE; HEPATITIS B ANTIBODY; LAMIVUDINE; VIRUS DNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUTATION; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENCE RISK; RECURRENT DISEASE; RETRANSPLANTATION; RETROSPECTIVE STUDY; SURVIVOR; TREATMENT FAILURE;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MUTATION; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 79953178253     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22226     Document Type: Article

References (40)

1. Hwang S, Lee SG, Ahn CS, Kim KH, Moon DB, Ha TY, et al. Prevention of hepatitis B recurrence after living donor liver transplantation: primary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy. Liver Transpl 2008; 14: 770-778. (Pubitemid 351895507)
2. Mohanty SR, Cotler SJ,. Management of hepatitis B in liver transplant patients. J Clin Gastroenterol 2005; 39: 58-63. (Pubitemid 40041346)
3. Terrault N, Roche B, Samuel D,. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl 2005; 11: 716-732. (Pubitemid 40975571)
4. Roche B, Samuel D,. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004; 10: S74-S85. (Pubitemid 39406104)
5. Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok AS,. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27: 213-222.
6. Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum Buschenfelde KH, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998; 27: 254-263.
7. Thung SN,. Histologic findings in recurrent HBV. Liver Transpl 2006; 12 (11 Suppl 2): S50-S53. (Pubitemid 44742526)
8. Yi NJ, Suh KS, Cho JY, Kwon CH, Lee KW, Joh JW, et al. Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2007; 13: 451-458. (Pubitemid 46444475)
9. Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, Roche B, Fallot G, et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 2008; 134: 1890-1899. (Pubitemid 351783254)
10. Hwang S, Lee SG, Park KM, Kim KH, Ahn CS, Oh HB, et al. Five-year follow-up of a hepatitis B virus-positive recipient of hepatitis B surface antigen-positive living donor liver graft. Liver Transpl 2006; 12: 993-997. (Pubitemid 43960377)
11. Bae SH, Yoon SK, Jang JW, Kim CW, Nam SW, Choi JY, et al. Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J Korean Med Sci 2005; 20: 816-820.
12. Kim JK, Lee HJ, Lee YJ, Chun JY, Lee IK, Lim YS, et al. Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers. J Virol Methods 2008; 149: 76-84.
13. Lupo J, Larrat S, Hilleret MN, Germi R, Boyer V, Nicod S, et al. Assessment of selective real-time PCR for quantitation of lamivudine and adefovir hepatitis B virus-resistant strains and comparison with direct sequencing and line probe assays. J Virol Methods 2009; 156: 52-58.
14. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS,. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44: 703-712. (Pubitemid 44433727)
15. Sohn YH, Oh HB, Ko SY, Lim YS, Kwon OJ,. Analysis of clinical characteristics and S gene mutation of hepatitis B virus (HBV) in patients with hepatitis B surface antigen RIA negative and HBV DNA positive [in Korean with English abstract]. Korean J Lab Med 2009; 29: 224-230.
16. Zanetti AR, Tanzi E, Manzillo G, Maio G, Sbreglia C, Caporaso N, et al. Hepatitis B variant in Europe. Lancet 1988; 2: 1132-1133.
17. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336: 325-329. (Pubitemid 20264145)
18. Cariani E, Ravaggi A, Tanzi E, Romanò L, Fiordalisi G, Bellati G, et al. Emergence of hepatitis B virus S gene mutant in a liver transplant recipient. J Med Virol 1995; 47: 410-415. (Pubitemid 26018997)
19. Carman WF, Trautwein C, van Deursen FJ, Colman K, Dornan E, McIntyre G, et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996; 24: 489-493. (Pubitemid 26295985)
20. Song DE, Jung DH, Hwang S, Park BH, Yu E,. Characterization of histopathological features that differentiate hepatitis b virus infection from acute cellular rejection. Korean J Pathol 2009; 43: 535-541.
21. Terrault NA, Zhou S, McCory RW, Pruett TL, Lake JR, Roberts JP, et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998; 28: 555-561. (Pubitemid 28363686)
22. Coleman PF, Chen YC, Mushahwar IK,. Immunoassay detection of hepatitis B surface antigen mutants. J Med Virol 1999; 59: 19-24. (Pubitemid 29362160)
23. La'ulu SL, Roberts WL,. The analytic sensitivity and mutant detection capability of six hepatitis B surface antigen assays. Am J Clin Pathol 2006; 125: 748-751.
24. Lo CM, Cheung ST, Ng IO, Liu CL, Lai CL, Fan ST,. Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance: successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin. Liver Transpl 2004; 10: 557-563. (Pubitemid 38443598)
25. Bock CT, Tillmann HL, Torresi J, Klempnauer J, Locarnini S, Manns MP, Trautwein C,. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122: 264-273. (Pubitemid 34116979)
26. Lo CM, Liu CL, Lau GK, Chan SC, Ng IO, Fan ST,. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005; 11: 807-813. (Pubitemid 40975583)
27. Herreros de Tejada Echanojáuregui A, Moreno Planas JM, Rubio González E, Portero Azorin F, Lõpez Monclús J, Revilla Negro J, et al. Adefovir dipivoxil therapy in liver transplant recipients with lamivudine-resistant hepatitis B virus. Transplant Proc 2005; 37: 1507-1508. (Pubitemid 40712101)
28. Lok AS,. Liver transplantation for patients with lamivudine-resistant HBV: what is the optimal prophylactic strategy? Liver Transpl 2005; 11: 490-493. (Pubitemid 40704058)
29. Gish RG, McCashland T,. Hepatitis B in liver transplant recipients. Liver Transpl 2006; 12 (11 Suppl 2): S54-S64. (Pubitemid 44742527)
30. Tan J, Lok AS,. Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B. Liver Transpl 2007; 13: 323-326. (Pubitemid 46444459)
31. Davies SE, Portmann BC, O'Grady JG, Aldis PM, Chaggar K, Alexander GJ, William s R,. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150-157.
32. Hwang S, Lee SG, Ahn CS, Kim KH, Moon DB, Ha TY, et al. An increase in deceased donor incidence alleviated the need for urgent adult living donor liver transplantation in a Korean high-volume center. Transplant Proc 2010; 42: 1497-1501.
33. Roche B, Feray C, Gigou M, Roque-Afonso AM, Arulnaden JL, Delvart V, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003; 38: 86-95. (Pubitemid 36775799)
34. Loomba R, Rowley AK, Wesley R, Smith KG, Liang TJ, Pucino F, Csako G,. Hepatitis B immunoglobulin and lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol 2008; 6: 696-700.
35. Locarnini S,. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2008; 2: 147-151. (Pubitemid 351650142)
36. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE 4th,. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10: 625-633. (Pubitemid 41224954)
37. Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ,. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52: 176-182.
38. Di Paolo D, Tisone G, Piccolo P, Lenci I, Zazza S, Angelico M,. Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation 2004; 77: 1203-1208. (Pubitemid 38580298)
39. Dan YY, Wai CT, Yeoh KG, Lim SG,. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis. Liver Transpl 2006; 12: 736-746.
40. Saab S, Ham MY, Stone MA, Holt C, Tong M,. Decision analysis model for hepatitis B prophylaxis 1 year after liver transplantation. Liver Transpl 2009; 15: 413-420.